Welcome to our dedicated page for Fibrogen news (Ticker: FGEN), a resource for investors and traders seeking the latest updates and insights on Fibrogen stock.
FibroGen Inc (NASDAQ: FGEN) is a clinical-stage biopharmaceutical company pioneering novel therapies for oncology and anemia through innovative HIF biology and antibody-drug conjugate research. This page serves as the definitive source for verified FibroGen news and official communications, providing stakeholders with timely updates on clinical developments and corporate milestones.
Investors and industry observers will find essential information including clinical trial results, regulatory submissions, and strategic partnership announcements. Our curated feed includes earnings reports, research publications, and manufacturing updates directly impacting FibroGen's progress in bringing targeted therapies to market.
Key content categories cover advancements in the company's HIF-PH inhibitor programs for anemia management, ADC oncology candidates, and updates from global collaborations. All materials are sourced from primary corporate disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to FibroGen's latest developments. Check regularly for critical updates on pipeline progress, peer-reviewed study data, and market-moving announcements relevant to FGEN shareholders and industry analysts.
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call with investors is scheduled for the same day at 5:00 p.m. ET. This call will provide insights into the company’s corporate and financial performance.
Investors can access the call via the FibroGen website, with a replay available for 7 days post-call. FibroGen focuses on developing therapeutics for unmet medical needs, including treatments for anemia in chronic kidney disease and other conditions.
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 3:40pm EST. The event's audio webcast will be accessible on the FibroGen Investor webpage, with a replay available for 30 days.
FibroGen focuses on developing innovative therapeutics, including roxadustat for various anemias and pamrevlumab for conditions like idiopathic pulmonary fibrosis and pancreatic cancer. The company has expanded into immuno-oncology and autoimmune research.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference from January 10-13. The session will be available on-demand starting January 10 at 7:00am EST.
Listeners can access the audio webcast via the 'Events & Presentations' section on FibroGen's Investor webpage, with a replay available for 30 days. FibroGen is focused on first-in-class therapeutics, including the development of roxadustat and pamrevlumab for various medical conditions.
FibroGen (FGEN) has extended its partnership with HiFiBiO Therapeutics by exercising an exclusive license for the anti-CCR8 monoclonal antibody program, HFB1011. This agreement involves a $35 million upfront payment plus potential milestones and royalty payments based on net sales. FibroGen gains exclusive global rights to develop products from this program, which targets CCR8, a receptor implicated in tumor immune suppression. The HFB1011 development candidate is expected to enter clinical trials in 2023, reinforcing FibroGen's focus on expanding its immuno-oncology pipeline.
FibroGen reported significant growth in Q3 2021, with total revenue reaching $156 million, a substantial increase from $44 million in Q3 2020. This surge includes a $120 million milestone payment from Astellas following EU approval of roxadustat for CKD-related anemia. The net income also rose to $49.8 million or $0.54 per share. Additionally, net product revenue from roxadustat sales in China totaled $13.4 million for the quarter, contributing to overall sales of $57.8 million.
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in two upcoming healthcare conferences. The first is the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:40 PM EST, followed by the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 AM EST. An audio webcast will be available on the company's Investor webpage, with replays accessible for 30 days. FibroGen focuses on developing first-in-class therapeutics, including roxadustat for anemia and pamrevlumab for various disorders.
FibroGen, Inc. (NASDAQ: FGEN) will release its Q3 2021 financial results on November 9, 2021, after market close. A conference call for investors will follow at 5:00 p.m. ET to discuss the company's financial performance.
Participants can access the live audio webcast on FibroGen's website. Dial-in numbers for the call are available for both U.S./Canada and international callers. A replay of the call will be accessible shortly after the event for seven days.
FibroGen (NASDAQ: FGEN) has announced that 18 presentations from its global Phase 3 roxadustat clinical program will be featured at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. Key highlights include 11 presentations focusing on roxadustat's efficacy in treating anemia related to chronic kidney disease (CKD) and 7 on CKD anemia epidemiology, underscoring its medical need. Roxadustat, an oral medication, is currently approved in several regions for CKD-related anemia and is in further regulatory reviews.
FibroGen announced positive topline results from the WHITNEY Phase 2 clinical study of roxadustat for treating chemotherapy-induced anemia (CIA). The study met its primary endpoint: maximum change in hemoglobin within 16 weeks without red blood cell transfusion. Ninety-two patients with non-myeloid malignancies participated, receiving doses of 2.0 mg/kg or 2.5 mg/kg of roxadustat three times per week. The drug was generally well tolerated, with no significant differences in adverse events based on dosage. Full results will be presented at a medical meeting later this year.
FibroGen and Astellas Pharma announced the European Commission's approval of EVRENZO™ (roxadustat) for treating anemia associated with chronic kidney disease (CKD) in adults. This marks the first oral HIF-PH inhibitor available in the EU. The approval, which follows a positive opinion from the European Medicines Agency, is based on Phase 3 clinical trials involving 9,600 patients, demonstrating efficacy in achieving target hemoglobin levels. The approval triggers a $120 million milestone payment from Astellas to FibroGen, alongside future royalties based on European sales.
FAQ
What is the current stock price of Fibrogen (FGEN)?
What is the market cap of Fibrogen (FGEN)?
